巨细胞病毒性前葡萄膜炎:法国系列临床表现与长期结局
69.4%表现为Posner-Schlossman综合征,30.6%为慢性非特异性前葡萄膜炎;94.2%对一线抗病毒诱导治疗有反应,73.5%复发,25.7%需青光眼手术。早期(≤700天)启动抗病毒治疗似乎减少青光眼手术需求,静脉与口服诱导方案在BCVA变化和复发方面似乎相似。
要点
- CMV前葡萄膜炎在本法国队列中表现为Posner-Schlossman综合征(69.4%)或慢性非特异性前葡萄膜炎(30.6%),未见Fuchs葡萄膜炎或内皮炎。
- 94.2%患者对一线抗病毒诱导治疗有反应,但73.5%出现复发,25.7%需青光眼手术。
- 早期(≤700天)启动抗病毒治疗似乎减少青光眼手术需求;静脉与口服诱导方案在BCVA变化和复发方面似乎相似。
核心结论
- CMV前葡萄膜炎在本法国队列中似乎具有特定表现,早期启动抗病毒治疗似乎减轻青光眼严重程度。
主要发现
- Posner-Schlossman综合征占69.4%,慢性非特异性前葡萄膜炎占30.6%,未见Fuchs葡萄膜炎或内皮炎病例。
- 基线平均BCVA为20/25,平均IOP为29.19 mm Hg;角膜后沉着物见于91.4%的病例,虹膜萎缩见于25.7%的病例。
- 诱导治疗采用口服缬更昔洛韦者占40%,静脉更昔洛韦者占60%;94.2%的患者对一线治疗有反应。
- 复发见于73.5%的病例,25.7%的病例需青光眼手术。
- 早期(≤700天)启动抗病毒治疗似乎减少青光眼手术需求;静脉与口服诱导治疗在BCVA变化和复发发生方面似乎相似。
关键数值与推荐
- 基线平均BCVA为20/25,平均IOP为29.19 mm Hg。
- 角膜后沉着物见于91.4%的病例,虹膜萎缩见于25.7%的病例。
- 口服缬更昔洛韦诱导占40%,静脉更昔洛韦诱导占60%。
- 94.2%的患者对一线治疗有反应,73.5%的病例复发,25.7%的病例需青光眼手术。
- 早期启动抗病毒治疗定义为≤700天。
临床怎么用
- 对于PCR阳性的免疫功能正常CMV前葡萄膜炎患者,可考虑抗病毒诱导治疗(静脉更昔洛韦或口服缬更昔洛韦)后口服缬更昔洛韦维持。
- 早期(≤700天)启动抗病毒治疗似乎可减少后续青光眼手术需求。
- 静脉与口服诱导方案在BCVA变化和复发方面似乎相似。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the characteristics of cytomegalovirus anterior uveitis (CMV AU) and the comparative response to 2 types of antiviral induction treatments. DESIGN: Retrospective, consecutive case series. METHODS: Consecutive immunocompetent patients with polymerase chain reaction-positive CMV AU were included. For each patient, best-corrected visual acuity (BCVA), intraocular pressure (IOP), clinical characteristics at baseline and latest visit, and number of relapses were recorded. All patients received an induction dose of intravenous (IV) ganciclovir or oral valganciclovir and a maintenance dose of oral valganciclovir. RESULTS: Thirty-six eyes of 35 patients were included. Mean age at diagnosis was 55.5 years. Mean follow-up was 4.13 years. Posner-Schlossman and chronic nonspecific AU were observed in 69.4% and 30.6% of cases, respectively. We did not observe any case of Fuchs uveitis or endotheliitis. At baseline, mean BCVA was 20/25 and mean IOP was 29.19 mm Hg. Keratic precipitates and iris atrophy were seen in 91.4% and 25.7% of cases. Induction therapy consisted of oral valganciclovir and IV ganciclovir in 40% and 60% of cases. A total of 94.2% of patients responded to the first line of therapy. Recurrence was reported in 73.5% of cases. Glaucoma surgery was necessary in 25.7% of cases. Early initiation of antiviral therapy (≤700 days) seemed to decrease the recourse to glaucoma surgery. Both IV and oral induction treatments seemed similar in terms of BCVA changes and occurrence of relapses. CONCLUSIONS: Characteristics of CMV AU seem to show specificities in this French cohort. Early initiation of antiviral therapy seems to reduce the severity of glaucoma.
引用
- Touhami S, Qu L, Angi M, et al. Cytomegalovirus Anterior Uveitis: Clinical Characteristics and Long-term Outcomes in a French Series. Am J Ophthalmol. 2018. PMID: 30055154. doi:10.1016/j.ajo.2018.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。